Overactive bladder is an highly prevalent syndrome involving up to 17% of the population in both western Europe and US and is often associated with detrusor overactivity. Significant improvement in the management of this condition has recently occurred cause the availability of new drugs. Methods: The Medline database has been extensively searched. Research has also involved industrial and private databases available online and specialised in the development of new drugs. Results: Antimuscarinics remain the gold standard in the management of detrusor overactivity although the condition mostly goes undiagnosed in non neurogenic patients suffering from overactive bladder syndrome. A number of receptors other than muscarinics have been investigated as possible new targets although no novel effective drugs have been yet developed. Conclusion: Antimuscarinic drugs dominate medical treatment of symptoms and signs associated with detrusor overactivity although new drugs will hopefully be available in the future based on alternative pathophysiological mechanism. © 2004 Elsevier B.V. All rights reserved.
Comparison of peripherally acting substance for treatment of detrusor overactivity: What is new; what is in the pipeline? / Tubaro, Andrea; DE NUNZIO, Cosimo. - In: EAU UPDATE SERIES. - ISSN 1570-9124. - 2:4 SPEC.ISS.(2004), pp. 161-169. [10.1016/j.euus.2004.09.001]
Comparison of peripherally acting substance for treatment of detrusor overactivity: What is new; what is in the pipeline?
TUBARO, ANDREA;DE NUNZIO, Cosimo
2004
Abstract
Overactive bladder is an highly prevalent syndrome involving up to 17% of the population in both western Europe and US and is often associated with detrusor overactivity. Significant improvement in the management of this condition has recently occurred cause the availability of new drugs. Methods: The Medline database has been extensively searched. Research has also involved industrial and private databases available online and specialised in the development of new drugs. Results: Antimuscarinics remain the gold standard in the management of detrusor overactivity although the condition mostly goes undiagnosed in non neurogenic patients suffering from overactive bladder syndrome. A number of receptors other than muscarinics have been investigated as possible new targets although no novel effective drugs have been yet developed. Conclusion: Antimuscarinic drugs dominate medical treatment of symptoms and signs associated with detrusor overactivity although new drugs will hopefully be available in the future based on alternative pathophysiological mechanism. © 2004 Elsevier B.V. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.